Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences Analyst Ratings

CLRB's stock price has decreased by -90.96% in the past year and price targets may not have had time to catch up.

• Total Analysts: 2
• Consensus Rating: Buy
• Price Target: $28.00
• Upside: +11,814.89%

Ratings History

Filter results

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jeff Jones Oppenheimer	Oppenheimer	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Dec 11, 2024
Jeff Jones Oppenheimer	Oppenheimer	Buy Maintains $14 → $12	Buy	Maintains	$14 → $12	+5,006.38%	Nov 19, 2024
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $14	Buy	Reiterates	$14	+5,857.45%	Oct 11, 2024
Jonathan Aschoff Roth MKM	Roth MKM	Strong Buy Maintains $20 → $28	Strong Buy	Maintains	$20 → $28	+11,814.89%	Mar 28, 2024
Jeff Jones Oppenheimer	Oppenheimer	Buy Reiterates $11 → $12	Buy	Reiterates	$11 → $12	+5,006.38%	Mar 28, 2024
Jonathan Aschoff Roth MKM	Roth MKM	Strong Buy Reiterates $20	Strong Buy	Reiterates	$20	+8,410.64%	Mar 4, 2024
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $3 → $4	Strong Buy	Maintains	$3 → $4	+1,602.13%	Nov 4, 2022
Jeff Jones Oppenheimer	Oppenheimer	Buy Initiates $55	Buy	Initiates	$55	+23,304.26%	Jul 18, 2022
Kevin DeGeeter Oppenheimer	Oppenheimer	Buy Initiates $50	Buy	Initiates	$50	+21,176.60%	Jul 1, 2020
Jason McCarthy Maxim Group	Maxim Group	Strong Buy Initiates $30	Strong Buy	Initiates	$30	+12,665.96%	Jun 23, 2020
Jonathan Aschoff Roth Capital	Roth Capital	Strong Buy Initiates $100	Strong Buy	Initiates	$100	+42,453.19%	Jan 21, 2020
Jonathan Aschoff Roth Capital	Roth Capital	Strong Buy Initiates $110	Strong Buy	Initiates	$110	+46,708.51%	Sep 13, 2019
Wangzhi Li Ladenburg Thalmann	Ladenburg Thalmann	Strong Buy Initiates $270	Strong Buy	Initiates	$270	+114,793.62%	Dec 21, 2016